CWC
HRTX icon

Carolinas Wealth Consulting’s Heron Therapeutics HRTX Stock Holding History

Carolinas Wealth Consulting’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-41,356
Closed -$91K – 414
2025
Q1 		$91K Hold
41,356
– – 0.02% 256
2024
Q4 		$63.3K Buy
41,356
+13,669
+49% +$22.2K 0.01% 325
2024
Q3 		$55.1K Buy
27,687
+5,857
+27% +$14K 0.01% 348
2024
Q2 		$76.4K Buy
21,830
+2,130
+11% +$6.54K 0.01% 302
2024
Q1 		$54.6K Buy
+19,700
New +$49.5K 0.01% 359

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Carolinas Wealth Consulting's HRTX Position: Q2 2025 in Review

Carolinas Wealth Consulting sold out of Heron Therapeutics (HRTX) in Q2 2025, closing a stake of 41,356 shares — an estimated $91K sold.

Carolinas Wealth Consulting first reported a position in HRTX in Q1 2024 and held it in 5 quarters. The position peaked at $91K in Q1 2025. 171 funds tracked by Wall St. Rank hold HRTX as of Q2 2025.

  • Carolinas Wealth Consulting reported no remaining Heron Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 41,356 Heron Therapeutics shares in Q2 2025, an estimated $91K.
  • Carolinas Wealth Consulting first reported a position in Heron Therapeutics in Q1 2024 and held it in 5 quarters.
  • Carolinas Wealth Consulting's Heron Therapeutics position peaked at $91K in Q1 2025.
  • 171 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2025.

Based on Carolinas Wealth Consulting's 13F filing for Q2 2025.